رجوع

RaySearch Laboratories AB (publ)

جودة البيانات: 100%

ذروة بيع

RSLBF

OTC Healthcare Medical - Healthcare Information Services

KWD 23.00

KWD 0.00 (0.00%)

القيمة السوقية: 822.17M

نطاق اليوم

KWD 23.00 KWD 23.00

نطاق 52 أسبوعًا

KWD 20.60 KWD 37.36

حجم التداول

متوسط 50 يوم / 200 يوم

KWD 25.46 / KWD 28.72

الإغلاق السابق

KWD 23.00

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Healthcare (627 نظير)

المقياس	السهم	وسيط القطاع
P/E	3.6	0.3
P/B	0.8	2.9
ROE %	24.5	3.7
Net Margin %	17.0	3.8
Rev Growth 5Y %	20.3	10.0
D/E	0.4	0.2

السعر المستهدف للمحللين

لا تتوفر تغطية محللين

تقديرات الأرباح

الفترة	تقدير ربحية السهم	تقدير الإيرادات	المحللون
FY2028	KWD 11.924 KWD 11.487 – KWD 12.361	1.8 B	1
FY2027	KWD 9.821 KWD 9.461 – KWD 10.181	1.6 B	1
FY2026	KWD 7.848 KWD 7.561 – KWD 8.136	1.4 B	1

النقاط الرئيسية

Revenue grew 20.31% annually over 5 years — strong growth

ROE of 24.47% indicates high profitability

Net margin of 16.95% shows strong profitability

Debt/Equity of 0.40 — conservative balance sheet

Generating 158.90M in free cash flow

P/E of 3.61 — trading at a low valuation

النمو

Revenue Growth (5Y)

20.31%

Revenue (1Y)12.77%

Earnings (1Y)11.93%

FCF Growth (3Y)-19.73%

الجودة

Return on Equity

24.47%

ROIC15.88%

Net Margin16.95%

Op. Margin21.74%

الأمان

Debt / Equity

0.40

Current Ratio1.70

Interest Coverage0.00

التقييم

P/E Ratio

3.61

P/B Ratio0.83

EV/EBITDA2.77

Dividend Yield0.01%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	12.77%	Revenue Growth (3Y)	14.68%
Earnings Growth (1Y)	11.93%	Earnings Growth (3Y)	67.11%
Revenue Growth (5Y)	20.31%	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	1.34B	Net Income (TTM)	227.80M
ROE	24.47%	ROA	11.44%
Gross Margin	92.42%	Operating Margin	21.74%
Net Margin	16.95%	Free Cash Flow (TTM)	158.90M
ROIC	15.88%	FCF Growth (3Y)	-19.73%
Safety
Debt / Equity	0.40	Current Ratio	1.70
Interest Coverage	0.00	Dividend Yield	0.01%
Valuation
P/E Ratio	3.61	P/B Ratio	0.83
P/S Ratio	0.61	PEG Ratio	2.76
EV/EBITDA	2.77	Dividend Yield	0.01%
Market Cap	822.17M	Enterprise Value	809.67M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	1.34B	1.19B	1.02B	843.65M	641.67M
Net Income	227.80M	203.51M	81.57M	23.78M	-47.32M
EPS (Diluted)	6.65	5.94	2.38	0.69	-1.38
Gross Profit	1.24B	1.09B	915.58M	748.66M	591.28M
Operating Income	292.30M	260.49M	114.88M	42.74M	-52.64M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	1.99B	2.09B	1.95B	1.88B	1.74B
Total Liabilities	1.01B	1.21B	1.22B	1.22B	1.12B
Shareholders' Equity	985.30M	876.71M	735.23M	657.16M	628.31M
Total Debt	394.80M	471.93M	529.36M	555.39M	561.40M
Cash & Equivalents	407.30M	462.74M	343.68M	160.27M	102.54M
Current Assets	970.70M	984.75M	802.45M	627.92M	516.37M
Current Liabilities	569.90M	703.82M	675.05M	614.10M	490.08M

درجات الاستراتيجيات

This stock passed the criteria for 5 strategies

Score = fit strength (0–100)

Rank = position among all matches

Custom Deep Value Investing (Seth Klarman)

#679 of 827

Growth Price/Sales Ratio Focus (Ken Fisher)

#238 of 618

Custom Contrarian Investing (David Dreman)

#219 of 670

Value Defensive Investing (Benjamin Graham)

#144 of 709

Value Value Investing (Warren Buffett)

#140 of 203

النشاط الأخير

دخل Deep Value Investing (Seth Klarman)

Mar 24, 2026

دخل Price/Sales Ratio Focus (Ken Fisher)

Mar 24, 2026

دخل Contrarian Investing (David Dreman)

Mar 24, 2026

دخل Defensive Investing (Benjamin Graham)

Mar 24, 2026

دخل Value Investing (Warren Buffett)

Mar 24, 2026